steroids and glp 1 Frontiers Glucagon-like peptide-1 (GLP-1) receptor agonists

Trulicity offers a simple, once-weekly way to control type 2 diabetes and prevent cardiovascular disease (CVD) or help with existing CVD

Ben Scherer | Foot and Ankle LA

list price as of April 2026 (Novo Nordisk published pricing)

World Obesity Federation, World Obesity Atlas 2023 Unsurprisingly, weight loss medications have captured innovators attention as potential solutions, however, the obesity market has a history of many false dawns, as drugs in the past failed to deliver meaningful efficacy while some had serious safety issues, e.g., Fen-Phen, which was eventually withdrawn from the market due to cardiac risks3

This study compared the cardiovascular protective effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) versus sodium-glucose cotransporter-2 (SGLT2) inhibitors in this population

At higher doses, reductions exceeded 40%